At nanoX we research emerging therapeutics and biotechnological breakthroughs aimed at educating our communities on the latest developments in genomics, longevity science, and precision medicine.
Why it matters
Advances in genomics, epigenetics, and cellular reprogramming are converging on a single idea: aging is not inevitable — it is a process that can be understood, measured, and eventually modified. nanoX exists to accelerate that pursuit.
We believe the next breakthroughs in longevity will come not from single experiments, but from connecting vast biological datasets across populations, tissues, and time.
Human longevity research operates on timescales that demand patience and rigour. We are committed to publishing what we learn — even when the answer is "not yet."
Research focus areas
Mapping genetic factors in aging and disease to identify targetable pathways for therapeutic intervention.
Developing novel biological tools and therapies that target the molecular mechanisms underlying aging and disease.
Applying computational methods and large-scale data analysis to accelerate discovery and personalise treatment.
We welcome inquiries from researchers, collaborators, and anyone passionate about the future of human health and longevity.